Clinical Trial: A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablets.

U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07285967) titled 'A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablets.' on Nov. 20.

Brief Summary: This is a Phase I clinical trial (protocol number: YR-011-B01) sponsored by Hangzhou Yirui Pharmaceutical Technology Co., Ltd., focusing on the novel oral small-molecule drug YR011 (active ingredient: PA032, a Kv1.3 channel blocker). The trial aims to evaluate the safety, tolerability, and pharmacokinetics (PK) of YR011 in healthy adult participants, and to determine the recommended dose for Phase II studies (targeting inflammatory bowel diseases like ulcerative colitis).

The trial has two stages: Single Ascending ...